Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyLuc Dirix, Erika Hamilton, István Takács et al.|Breast Cancer Research and Treatment|2017Cited by 761
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyRobert Pirker, Kenneth J. O’Byrne, Rodryg Ramlau et al.|The Lancet Oncology|2011Cited by 574